Adrenal responses to pharmacological interruption of the renin-angiotensin system in sodium-restricted normal man

G. H. Williams, N. K. Hollenberg, C. Brown, J. M. Mersey

Research output: Contribution to journalArticle

Abstract

We assessed the role of the renin-angiotensin system in the control of aldosterone secretion in response to sodium restriction in 62 normal subjects. Both saralasin, an angiotensin II antagonist, and SQ 20881, a converting enzyme inhibitor, induced a dose-related decrease in plasma aldosterone levels when the renin-angiotensin system was activated by restriction of sodium intake. Two types of experiments were performed with saralasin. In the first set, a dose-response relationship was established 20 min after beginning infusions ranging from 0.03-1.0 μg/kg/min. The optimal dose was 0.1 μg/kg/min, with a reduction in aldosterone levels of -10.1 ± 3.8 ng/dl (P

Original languageEnglish (US)
Pages (from-to)725-731
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume47
Issue number4
StatePublished - 1978
Externally publishedYes

Fingerprint

Angiotensins
Renin-Angiotensin System
Aldosterone
Renin
Saralasin
Sodium
Pharmacology
Teprotide
Enzyme Inhibitors
Angiotensin II
Plasmas
Experiments

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Adrenal responses to pharmacological interruption of the renin-angiotensin system in sodium-restricted normal man. / Williams, G. H.; Hollenberg, N. K.; Brown, C.; Mersey, J. M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 47, No. 4, 1978, p. 725-731.

Research output: Contribution to journalArticle

Williams, G. H. ; Hollenberg, N. K. ; Brown, C. ; Mersey, J. M. / Adrenal responses to pharmacological interruption of the renin-angiotensin system in sodium-restricted normal man. In: Journal of Clinical Endocrinology and Metabolism. 1978 ; Vol. 47, No. 4. pp. 725-731.
@article{fedc0c09623c495682e19249a5617ff2,
title = "Adrenal responses to pharmacological interruption of the renin-angiotensin system in sodium-restricted normal man",
abstract = "We assessed the role of the renin-angiotensin system in the control of aldosterone secretion in response to sodium restriction in 62 normal subjects. Both saralasin, an angiotensin II antagonist, and SQ 20881, a converting enzyme inhibitor, induced a dose-related decrease in plasma aldosterone levels when the renin-angiotensin system was activated by restriction of sodium intake. Two types of experiments were performed with saralasin. In the first set, a dose-response relationship was established 20 min after beginning infusions ranging from 0.03-1.0 μg/kg/min. The optimal dose was 0.1 μg/kg/min, with a reduction in aldosterone levels of -10.1 ± 3.8 ng/dl (P",
author = "Williams, {G. H.} and Hollenberg, {N. K.} and C. Brown and Mersey, {J. M.}",
year = "1978",
language = "English (US)",
volume = "47",
pages = "725--731",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Adrenal responses to pharmacological interruption of the renin-angiotensin system in sodium-restricted normal man

AU - Williams, G. H.

AU - Hollenberg, N. K.

AU - Brown, C.

AU - Mersey, J. M.

PY - 1978

Y1 - 1978

N2 - We assessed the role of the renin-angiotensin system in the control of aldosterone secretion in response to sodium restriction in 62 normal subjects. Both saralasin, an angiotensin II antagonist, and SQ 20881, a converting enzyme inhibitor, induced a dose-related decrease in plasma aldosterone levels when the renin-angiotensin system was activated by restriction of sodium intake. Two types of experiments were performed with saralasin. In the first set, a dose-response relationship was established 20 min after beginning infusions ranging from 0.03-1.0 μg/kg/min. The optimal dose was 0.1 μg/kg/min, with a reduction in aldosterone levels of -10.1 ± 3.8 ng/dl (P

AB - We assessed the role of the renin-angiotensin system in the control of aldosterone secretion in response to sodium restriction in 62 normal subjects. Both saralasin, an angiotensin II antagonist, and SQ 20881, a converting enzyme inhibitor, induced a dose-related decrease in plasma aldosterone levels when the renin-angiotensin system was activated by restriction of sodium intake. Two types of experiments were performed with saralasin. In the first set, a dose-response relationship was established 20 min after beginning infusions ranging from 0.03-1.0 μg/kg/min. The optimal dose was 0.1 μg/kg/min, with a reduction in aldosterone levels of -10.1 ± 3.8 ng/dl (P

UR - http://www.scopus.com/inward/record.url?scp=0018171726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018171726&partnerID=8YFLogxK

M3 - Article

C2 - 400731

AN - SCOPUS:0018171726

VL - 47

SP - 725

EP - 731

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -